Compare INNV & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | PHAR |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | 2020 |
| Metric | INNV | PHAR |
|---|---|---|
| Price | $11.88 | $13.42 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 432.0K | 5.1K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $853,699,000.00 | N/A |
| Revenue This Year | $12.85 | $10.04 |
| Revenue Next Year | $8.88 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 11.76 | N/A |
| 52 Week Low | $3.13 | $9.54 |
| 52 Week High | $12.64 | $21.34 |
| Indicator | INNV | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 69.14 | 42.81 |
| Support Level | $7.33 | $12.88 |
| Resistance Level | $12.64 | $13.61 |
| Average True Range (ATR) | 0.75 | 0.50 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 66.67 | 4.47 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.